Glioblastoma and Individualized Therapies
Retrospective Analysis of Glioblastoma Patients With Immune Therapies
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
The treatment of patients with World Health Organization (WHO) grade 4 malignant glioma has not seen any significant breakthrough the past years. Following surgery and radio / chemotherapy patients still experience a very high recurrence risk and the prognosis is dismal. The investigators observed patients with grade IV malignant glioma receiving individualized treatment based on their molecular profile including fully personalized vaccines.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 11, 2022
CompletedFirst Posted
Study publicly available on registry
May 2, 2022
CompletedMarch 1, 2024
February 1, 2024
April 11, 2022
February 29, 2024
Conditions
Interventions
Personalized neoantigen vaccination
Eligibility Criteria
You may qualify if:
- malignant glioma, IDH WT
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Zentrum für Humangenetik Tübingen
Tübingen, Germany
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 11, 2022
First Posted
May 2, 2022
Last Updated
March 1, 2024
Record last verified: 2024-02